Authors Title Date Time
Podium presentations
Matthijs Versteegh CONDITION SPECIFIC UTILITIES: IMPACT ON ICER IN A MARKOV MODEL FOR MULTIPLE SCLEROSIS Monday 15:45 – 16:45 session II
Issue Panels
Margreet Franken, Michel van Agthoven, Saskia Knies, Carin Uyl de Groot THE TRUTH, THE WHOLE TRUTH, AND NOTHING BUT THE TRUTH: SHOULD WE STICK TO PRAGMATIC INCREMENTALISM OR IS IT TIME TO TAKE COST-EFFECTIVENESS ANALYSES UP TO THE LEVEL OF DISEASE MODELLING? Tuesday 15:15 – 16:15 session III
Workshops
Saskia de Groot, Hedwig Blommestein, Margreet Franken, Annet van Abeelen CHALLENGES AND SOLUTIONS TO SUCCESSFULLY DETERMINE REAL-WORLD COST-EFFECTIVENESS Tuesday 16:30 – 17:30 session III
Posters
Brenda Leeneman, Margreet Franken, Carin Uyl de Groot IMPROVED SURVIVAL WITH IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN REAL-WORLD CLINICAL PRACTICE: FIRST RESULTS OF THE DUTCH MELANOMA TREATMENT REGISTRY Monday 15:30 – 19:45 session II [PCN62]
Melinde Boland, Apostolos Tsiachristas, Maureen Rutten-van Mölken COPD PERFORMANCE INDICATORS  IN AN INTEGRATED CARE PROGRAM AND ITS IMPACT ON HEALTH OUTCOMES: THE RECODE CLUSTER RANDOMIZED TRIAL Monday 15:45:19:45 session II [PRS68]
Remziye Zaim, Saskia de Groot, Carin Uyl-de Groot RECURRENT LARYNGEAL CARCINOMA PET STUDY (RELAPS): COST ANALYSIS OF 18F-FDG PET IN PATIENTS WITH SUSPECTED RECURRENT LARYNGEAL CANCER PREVIOUSLY TREATED WITH RADIOTHERAPY Monday 08:30 – 14:15 SESSION I [PMD51]
Margreet Franken, Margreet Franken, Brenda Leeneman, Maartje Schouwenburg, Anouk Jochems, Michel Wouters, Alfons van den Eertwegh, John Haanen, Carin Uyl-de Groot, Koos van der Hoeven THE DUTCH MELANOMA TREATMENT REGISTRY AS BLUEPRINT FOR USING REGISTRY DATA TO IMPROVE HEALTH CARE DECISION MAKING Monday 15:45 – 19:45 session II [PCN344]
R.Maan, Remziye Zaim, Carin Uyl de Groot REAL-WORLD MEDICAL COSTS OF ANTIVIRAL THERAPY AMONG PATIENTS WITH CHRONIC HCV INFECTION AND ADVANCED HEPATIC FIBROSIS Tuesday 15:00 – 19:15 session IV [PGI14]
Leander Buisman, J.J. Luime, M. Oppe, J.M. Hazes, Maureen Rutten van Molken A FIVE-YEAR MODEL TO ASSESS THE COST-EFFECTIVENESS OF NEW DIAGNOSTIC TESTS IN THE EARLY DIAGNOSIS OF RHEUMATOID ARTHRITIS Monday 08:30 – 14:15 SESSION I [PMD82/C16]
Lucas Goossens, Elly Stolk, Melinde Boland, Maureen Rutten van Molken ASSESSING COPD PATIENTS BURDEN OF DISEASE IN A FOLD-IN-FOLD-OUT DISCRETE CHOICE EXPERIMENT Monday 15:30 – 19:45 session II [PRS56/N11]
Simone Huygens, Rutten-van Mölken, Bekkers, Bogers, Bouten, Chamuleau, de Jaegere, Kappetein, Kluin, van Mieghem, Versteegh, Witsenburg, Takkenberg DEVELOPMENT OF A CONCEPTUAL MODEL FOR EARLY HEALTH TECHNOLOGY ASSESSMENT OF TISSUE-ENGINEERED HEART VALVES Monday 08:30 – 14:15 SESSION I [PCV115]
Nick Verbeek, Apostolos Tsiachristas, Margreet Franken, Marc Koopmanschap, Maureen Rutten-van Molken A TRIPLE AIM FRAMEWORK FOR THE PERFORMANCE ASSESSMENT OF DISEASE MANAGEMENT Monday 08:30 – 14:15 SESSION I [PCV150]
S.Soon, Ken Redekop A COST-EFFECTIVENESS ANALYSIS OF ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES AND COLORECTAL CANCER Monday 15:30 – 19:45 session II [PCN183]
Nasuh Buyukkaramikli, Annemieke Leunis, Johan L Severens ECONOMIC EVALUATION OF TARGETED ANTIFUNGAL TREATMENT SEQUENCING STRATEGIES FOR INVASIVE ASPERGILLOSIS BASED ON REAL WORLD DATA: THE CASE OF DUTCH CLINICAL PRACTICE Tuesday 08:30 – 13:45 session III [PIN60]
Martine Hoogendoorn, Melinde Boland, Lucas Goossens, M. Oppe, Elly Stolk, Maureen Rutten DEVELOPMENT OF AN EQ-5D RESPIRATORY BOLT-ON Wednesday 08:30 – 13:45 session V [PRM181]
Martine Hoogendoorn, Feenstra, Asukai, Briggs, Borg, dal Negro, Hansen, Jansson Wacker, Risebrough, Samyshkin, Leidl, Rutten van-Mölken PATIENT HETEROGENEITY IN COST-EFFECTIVENESS MODELS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): ARE CURRENT MODELS SUITABLE TO EVALUATE PERSONALIZED MEDICINE Wednesday 08:30 – 13:45 session V [PRM69]
Nattawut Thongkong, Pieter van Baal, Johan Severens INCLUDING HUMAN RESOURCE CONSTRAINTS IN HEALTH ECONOMIC EVALUATIONS Wednesday 08:30 – 13:45 session V [PRM36]
Nick Verbeek, Apostolos Tsiachristas, Margreet Franken, Marc Koopmanschap, Maureen Rutten-van Molken PERFORMANCE SCORE EXTRACTION FROM PANEL DATA FOR MULTI-CRITERIA DECISION ANALYSIS (MCDA) USING A REGRESSION-BASED APPROACH Wednesday 08:30 – 13:45 session V [PRM203]
M.J. Nuijten, Ken Redekop HOW TO HANDLE LEVELS OF EVIDENCE IN HEALTH ECONOMIC MODELLING Wednesday 08:30 – 13:45 session V [PRM76]